Adjuvant Herceptin^® delivers high cure rates in HER2-positive early breast cancer

Use of adjuvant Herceptin^® has been investigated in a global programme of four large multicentre, randomised clinical trials involving more than 13,000 women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC).

The HERA study was the basis for obtaining approval for a label in the EU and rest of the world countries.

• HERA^1,2
• NSABP B-31^3,4
• NCCTG N9831^3,4
• BCIRG 006⁵

Figure 2.1 Designs of major Herceptin® adjuvant trials6 (reproduced by kind permission of The Oncologist© AlphaMed Press)